Anti-BCMA CAR-NK Cell Therapy for the Relapsed or Refractory Multiple Myeloma

NCT05008536 EARLY_PHASE1 UNKNOWN

The purpose of this study is to infuse BCMA CAR-NK cells（Umbilical \& Cord Blood (CB) Derived CAR-Engineered NK Cells） to the patients with relapsed and refractory multiple myeloma (MM), to assess the safety and feasibility of this strategy. The CAR enables the NK cells to recognize and kill the MM cells by targeting of BCMA, a protein expressed of the surface of the malignant plasma cells in MM patients.

Details

Lead sponsor	Xinqiao Hospital of Chongqing
Phase	EARLY_PHASE1
Status	UNKNOWN
Enrolment	27
Start date	Fri Oct 01 2021 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Fri Sep 01 2023 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

• Multiple Myeloma, Refractory

Interventions

• Anti-BCMA CAR-NK Cells
• Fludarabine
• Cytoxan

Countries

China